UA117342C2 - Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку - Google Patents

Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку

Info

Publication number
UA117342C2
UA117342C2 UAA201409643A UAA201409643A UA117342C2 UA 117342 C2 UA117342 C2 UA 117342C2 UA A201409643 A UAA201409643 A UA A201409643A UA A201409643 A UAA201409643 A UA A201409643A UA 117342 C2 UA117342 C2 UA 117342C2
Authority
UA
Ukraine
Prior art keywords
methods
cancer
сdkі
relates
compounds
Prior art date
Application number
UAA201409643A
Other languages
English (en)
Inventor
Ігор Б. Ронінсон
Дональд К. Портер
Марк П. Вентланд
Original Assignee
Сенекс Біотекнолоджи Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сенекс Біотекнолоджи Інк. filed Critical Сенекс Біотекнолоджи Інк.
Publication of UA117342C2 publication Critical patent/UA117342C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

Даний винахід стосується сполук та способів інгібування шляху інгібітора циклінзалежної кінази (CDKI). Конкретніше, даний винахід стосується сполук та способів інгібування шляху CDKI для досліджень та впливу на пов'язані зі старінням та інші пов'язані з CDKI захворювання. Даний винахід пропонує нові сполуки, які мають покращену розчинність та/або дієвість, та способи їх застосування. У різних аспектах даний винахід стосується лікування раку. Даний винахід пропонує способи хіміопрофілактики та попередження рецидивів та метастазування пухлини. Даний винахід додатково пропонує діагностичні методики для лікування певних типів раку. Згідно з даним винаходом використовують специфічні інгібітори CDK8/19 та/або вимірювання рівнів CDK8 у пацієнта.
UAA201409643A 2012-02-02 2013-02-01 Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку UA117342C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US201261673419P 2012-07-19 2012-07-19
PCT/US2013/024515 WO2013116786A1 (en) 2012-02-02 2013-02-01 Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer

Publications (1)

Publication Number Publication Date
UA117342C2 true UA117342C2 (uk) 2018-07-25

Family

ID=47716178

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201409643A UA117342C2 (uk) 2012-02-02 2013-02-01 Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку

Country Status (16)

Country Link
US (2) US9321737B2 (uk)
EP (2) EP3431087A1 (uk)
JP (1) JP6193268B2 (uk)
KR (1) KR20150023223A (uk)
CN (1) CN104363913B (uk)
AU (1) AU2013214783B2 (uk)
BR (1) BR112014019052A8 (uk)
CL (1) CL2014002062A1 (uk)
CO (1) CO7151516A2 (uk)
EA (2) EA028595B1 (uk)
GE (1) GEP201706688B (uk)
MY (1) MY165446A (uk)
PH (1) PH12014501862A1 (uk)
SG (1) SG11201404596UA (uk)
UA (1) UA117342C2 (uk)
WO (1) WO2013116786A1 (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018891A1 (en) * 2012-07-27 2014-01-30 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
BR112015003698A2 (pt) * 2012-08-23 2017-07-04 Hoffmann La Roche compostos, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método para o tratamento de câncer
US9636342B2 (en) 2012-11-01 2017-05-02 University Of South Carolina Method for treating prostate cancer
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
BR112016014760A2 (pt) 2013-12-24 2017-12-12 Harvard College composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína
JP6529085B2 (ja) * 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
CA2959762A1 (en) * 2014-06-10 2016-02-04 University Of South Carolina Methods and compositions for treatment of her-positive cancers
WO2016100782A1 (en) 2014-12-18 2016-06-23 University Of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
EP3294418A4 (en) * 2015-05-08 2019-01-02 President and Fellows of Harvard College Targeted selection of patients for treatment with cortistatin derivatives
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017076968A1 (en) 2015-11-03 2017-05-11 Lu License Ab Compounds for treatment of hypoproliferative disorders
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
JP7198489B2 (ja) * 2016-03-23 2023-01-04 国立大学法人 岡山大学 リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
US11578067B2 (en) * 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
WO2018156858A1 (en) * 2017-02-23 2018-08-30 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
CA3058880A1 (en) * 2017-04-03 2018-10-11 Kyoto Pharmaceutical Industries, Ltd. Novel cyclin-dependent kinase 8 and/or 19 inhibitor
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
JP7392954B2 (ja) * 2017-09-18 2023-12-06 シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー トリプルネガティブ乳癌の治療方法
US11261184B2 (en) 2017-10-02 2022-03-01 Boehringer Ingelheim International Gmbh [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
AU2020216498A1 (en) 2019-02-01 2021-09-23 Senex Biotechnology, Inc Bicyclic pyridine compositions and methods of using the same for cancer therapy
WO2022107877A1 (ja) 2020-11-20 2022-05-27 オリヅルセラピューティクス株式会社 成熟化剤
KR20230145101A (ko) 2021-02-09 2023-10-17 오리즈루 세라퓨틱스 가부시키가이샤 성숙화제
WO2022204534A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
KR20240067089A (ko) 2021-09-27 2024-05-16 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T 세포의 제조 방법
WO2023095801A1 (ja) 2021-11-24 2023-06-01 レグセル株式会社 ヒト誘導性制御性ｔ細胞およびその作製方法
TW202334397A (zh) 2021-11-24 2023-09-01 日商雷格細胞股份有限公司 用於治療或預防t細胞相關疾病之醫藥組合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
CA2306082A1 (en) * 1997-10-27 1999-05-06 Agouron Pharmaceuticals, Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
EP1615636A1 (en) * 2003-04-10 2006-01-18 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
CA2652341A1 (en) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc. Identification of cdki pathway inhibitors
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Also Published As

Publication number Publication date
JP6193268B2 (ja) 2017-09-06
EA032429B1 (ru) 2019-05-31
WO2013116786A1 (en) 2013-08-08
KR20150023223A (ko) 2015-03-05
AU2013214783A1 (en) 2014-08-28
GEP201706688B (en) 2017-06-26
US20170071942A1 (en) 2017-03-16
CN104363913B (zh) 2018-08-21
AU2013214783B2 (en) 2017-07-06
MY165446A (en) 2018-03-22
EP3431087A1 (en) 2019-01-23
CL2014002062A1 (es) 2015-03-20
CO7151516A2 (es) 2014-12-29
EA028595B1 (ru) 2017-12-29
PH12014501862A1 (en) 2014-11-24
BR112014019052A2 (uk) 2017-06-20
JP2015506376A (ja) 2015-03-02
EP2809324A1 (en) 2014-12-10
BR112014019052A8 (pt) 2017-07-11
EA201491399A1 (ru) 2015-04-30
CN104363913A (zh) 2015-02-18
US10993945B2 (en) 2021-05-04
US20140038958A1 (en) 2014-02-06
EA201791284A1 (ru) 2017-10-31
SG11201404596UA (en) 2014-10-30
US9321737B2 (en) 2016-04-26
EP2809324B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
UA117342C2 (uk) Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
PH12016502355A1 (en) Pharmaceutical composition
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
UA115983C2 (uk) Інгібітори днк-пк
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MY185103A (en) Bezylamine derivatives as inhibitors of plasma kallikrein
IN2015DN01151A (uk)
MD4659B1 (ro) Polimorf al inhibitorilor SYK
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
MY177344A (en) Compounds and their methods of use
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX362550B (es) Inhibidores ciclicos de glutaminasa.
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
NZ726695A (en) Gls1 inhibitors for treating disease
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.